Vanda Pharmaceuticals Halts Anxiety Drug Program After Phase III Trial Failure
Vanda Pharmaceuticals' stock fell after its anxiety drug failed a Phase III trial, and the company then put the program on hold.
2newsrooms
2articles
13 hoursrunning
Oct 14first seen
Ask Scout
Scout answers questions about this story using only the coverage below.
Coverage over time
Articles
| Oct 15, 3:15 AM | seekingalpha.com | Vanda puts anxiety drug program on hold after Phase III setback |
| Oct 14, 2:24 PM | investing.com | Vanda Pharmaceuticals stock falls after anxiety drug trial fails |